AQP4 and Alzheimer disease: Indeed, a number of astrocytic changes have been described in AD mouse models and human pathology, like detachment of astrocyte end-feet from the BBB, reduction of end-feet metabolism including loss of astrocytic glucose transporter 1 and of AQP4, and an overall impaired perivascular drainage of solutes [30, 57, 58].